Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Sep 2019 10:53 AM
RNS
Director Dealings / Market Share Purchase
04 Sep 2019 07:00 AM
RNS
Oxford Biomedica Interim Results
02 Sep 2019 09:31 AM
RNS
Total Voting Rights
23 Aug 2019 11:06 AM
RNS
Director Dealings / Market Share Purchase
09 Aug 2019 12:00 PM
RNS
Notice of Interim Results
01 Aug 2019 09:18 AM
RNS
Total Voting Rights
25 Jul 2019 02:17 PM
RNS
Director Dealings / Market Share Purchase
01 Jul 2019 11:03 AM
EQS
Oxford BioMedica (OXB): Eying up long-term value
01 Jul 2019 10:01 AM
RNS
Block listing Interim Review
01 Jul 2019 09:32 AM
RNS
Total Voting Rights
28 Jun 2019 07:00 AM
RNS
Repayment of Debt Facility
26 Jun 2019 02:52 PM
RNS
Director Dealings / Market Share Purchase
26 Jun 2019 07:00 AM
RNS
OXB and Santen enter R&D collaboration
25 Jun 2019 07:00 AM
RNS
Board Change
18 Jun 2019 07:15 AM
EQS
Oxford BioMedica (OXB): De-leveraging the balan...
10 Jun 2019 02:34 PM
RNS
Director/PDMR Shareholding
06 Jun 2019 01:08 PM
RNS
Axovant update on 1st cohort of Sunrise-PD trial
06 Jun 2019 11:39 AM
RNS
Holding(s) in Company
05 Jun 2019 12:06 PM
RNS
Holdings in Company
04 Jun 2019 05:38 PM
RNS
Holdings in Company
04 Jun 2019 09:59 AM
RNS
Total Voting Rights
03 Jun 2019 06:06 PM
RNS
Holding(s) in Company
03 Jun 2019 10:31 AM
RNS
Total Voting Rights
29 May 2019 06:19 PM
RNS
Exercise of Subscription Option by Novo Holdings
29 May 2019 01:06 PM
RNS
Result of AGM
28 May 2019 07:00 AM
RNS
Strategic Investment by Novo Holdings A/S
23 May 2019 06:04 PM
RNS
Director Dealings / Market Share Purchase
02 May 2019 02:53 PM
RNS
Long Term Incentive Plan Option Grant
01 May 2019 12:52 PM
RNS
REPLACEMENT: Total Voting Rights
01 May 2019 11:33 AM
RNS
Total Voting Rights
30 Apr 2019 05:38 PM
RNS
Holdings in Company
30 Apr 2019 01:35 PM
RNS
Oxford Biomedica to present at the ASGCT
30 Apr 2019 01:15 PM
RNS
Axovant doses second cohort of AXO-Lenti-PD
25 Apr 2019 03:38 PM
RNS
Director Dealings / Market Share Purchase
23 Apr 2019 01:47 PM
RNS
Deferred Bonus Plan and LTIP Option Grants
23 Apr 2019 11:38 AM
RNS
Director Dealings / Market Share Transactions
18 Apr 2019 05:33 PM
RNS
Exercise of warrants
18 Apr 2019 07:00 AM
RNS
Annual Report and Accounts & AGM Notification
02 Apr 2019 07:15 AM
EQS
Oxford BioMedica (OXB): Deal-making drives firs...
01 Apr 2019 11:40 AM
RNS
Total Voting Rights
26 Mar 2019 12:57 PM
RNS
Director Dealings / Market Share Purchase
26 Mar 2019 08:25 AM
RNS
Japanese approval of Kymriah® (tisagenlecleucel)
14 Mar 2019 07:00 AM
RNS
Preliminary Results
12 Mar 2019 07:00 AM
RNS
OXB announces R&D collaboration with Microsoft
11 Mar 2019 10:38 AM
RNS
Axovant's update on Phase 2 trial of AXO-Lenti-PD
01 Mar 2019 09:30 AM
RNS
Total Voting Rights
25 Feb 2019 12:23 PM
RNS
Director Dealings / Market Share Purchase
08 Feb 2019 07:00 AM
RNS
Notice of Results
07 Feb 2019 11:49 AM
RNS
Director/PDMR Shareholding
07 Feb 2019 09:22 AM
RNS
Update on programmes outlicensed to Sanofi

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings